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a  b  s  t  r  a  c  t
Dinitrotoluene  (DNT)  is a  nitroaromatic  explosive  that  exists  as  six  isomers;  two  major  isomers  (2,4-  and
2,6-DNT)  and  four  minor  isomers  (2,3-,  2,5-,  3,4-,  and  3,5-DNT).  DNT  has  been  found  in soil,  surface  water,
and groundwater  near  ammunition  production  plants.  The  major  isomers  of  DNT  are  classified  as  “likely
to  cause  cancer  in  humans.”  In  vitro  studies  have  provided  conflicting  data  regarding  the  genotoxicity  of
the minor  isomers.  Studies  indicate  that  metabolism  in the  gut  and  liver  are  necessary  to  convert  DNT  to
genotoxic  compounds.  As  such,  in  the  present  study  the  genotoxicity  of  isomers  of  DNT  was  assessed  using
two in  vivo  genotoxicity  assays.  The  Comet  assay  was  used  to detect  DNA  damage  in  liver  cells  from  male
Sprague-Dawley  rats  following  oral  exposure  (14-day)  to individual  isomers  of  DNT.  The micronucleus
assay  was  conducted  using  flow  cytometric  analysis  to detect  chromosomal  damage  in  peripheral  blood.
Treatment  with  2,3-,  3,4-,  2,4-,  2,5-  and  3,5-DNT  did  not  induce  DNA  damage  in  liver  cells  or  increase  the
frequency  of  micronucleated  reticulocytes  (MN-RET)  in  peripheral  blood  at the  doses  tested.  Treatment
with 2,6-DNT  induced  DNA  damage  in liver  tissue  at all doses  tested,  but  did  not  increase  the  frequency
of  micronucleated  reticulocytes  (MN-RET)  in peripheral  blood.  Thus,  2,4-DNT  and  the  minor  isomers
were  not  genotoxic  under  these  test  conditions,  while  2,6-DNT  was  genotoxic  in  the  target  tissue, the
liver.  These  results  support  previous  research  which  indicated  that  the  hepatocarcinogenicity  of  technical
grade  DNT  (TG-DNT)  could  be  attributed  to the  2,6-DNT  isomer.
Published by Elsevier B.V.
1. Introduction
Dinitrotoluene (DNT) is used to make polyurethane foams, dyes,
and explosives and ammunition. Technical grade DNT (TG-DNT),
is composed of approximately 76.5% 2,4-DNT, 18.8% 2,6-DNT, and
4.7% minor isomers (2.43% 3,4-DNT, 1.54% 2,3-DNT, 0.69% 2,5-DNT,
and 0.04% 3,5-DNT). DNTs are common soil contaminants at muni-
tions manufacturing sites, entering the environment as a result
of spills occurring during manufacturing processes, open burn-
ing/incineration, seepage from landfills and wastewater holding
facilities, and leaking of buried ammunition wastes [1,2]. Although
DNT entering the environment is largely comprised of the major
isomers (2,4-, 2,6-DNT), the minor isomers (2,3-, 2,5-, 3,4-, and
3,5-DNT) have also been found in the soil and water around Army
installations.
The major isomers are listed by the US Environmental Protection
Agency (USEPA) as probable human carcinogens based on can-
cer bioassays conducted with mixtures of DNT isomers. Although
two of the three cancer bioassays determined that 2,4-/2,6-DNT
and TG-DNT were hepatocarcinogenic in rats [3,4], the third study
∗ Corresponding author. Tel.: +1 410 436 7749; fax: +1 410 436 6710.
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found that 2,4-/2,6-DNT was not an hepatocarcinogen [5].  The dif-
ferences in carcinogenic effects reported in these studies have been
attributed to differences in the mixtures of DNT isomers used (TG-
DNT vs. 98% and 95% 2,4-DNT, respectively), prompting a series of
investigations on the carcinogenic potential of the individual iso-
mers. In vivo initiation–promotion assays demonstrated 2,6-DNT to
be a complete hepatocarcinogen and showed only weak promoting
activity for 2,4-DNT [6–8]. In a one-year study, pure 2,4-DNT was
shown to be non-carcinogenic and the cancer rate in rats given
TG-DNT was  approximately half that of 2,6-DNT, suggesting that
not only is 2,6-DNT likely the carcinogenic isomer, but that the
other isomers may  compete with 2,6-DNT in the metabolic pro-
cess that produces the active metabolite responsible for the cancer
[9]. Although considerable research focused on the major isomers,
limited data is available for the minor isomers.
Although bacterial mutagenicity studies have shown the minor
isomers to be mutagenic in several strains of bacteria (TA98,
TA1538, TA100, and TM677) [10–13],  the minor isomers were
not genotoxic and did not induce morphological transformation
in in vitro assays in mammalian cells (CHO/HPGRT, SHE) [14,15].
Treatment of primary rat hepatocyte cultures with the individual
minor isomers also did not result in an increase in unscheduled DNA
synthesis (UDS), indicating that the minor isomers do not induce
increases in DNA damage/repair in the target organ [16]. All of this
1383-5718/$ – see front matter. Published by Elsevier B.V.
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work, however, was conducted in vitro and is likely not reflective of
the genotoxicity or carcinogenic potential of these compounds as
in vitro assays have been labeled as not predictive of carcinogenic-
ity for this class of chemicals [17]. DNTs and other nitroaromatic
compounds are metabolically activated through nitroreduction and
oxidative pathways in the liver and the gut [18,19],  making in vivo
assessments necessary. An in vivo investigation of the ability of
DNTs to initiate liver cancer demonstrated that the minor isomers
do not increase the altered foci that precede development of neo-
plasms and carcinomas [7].  In vivo assessments of the genotoxicity
of the minor isomers are lacking.
To evaluate the in vivo genotoxicity of the individual isomers of
DNT, the peripheral blood micronucleus assay and the liver Comet
assay were conducted. Tissues for the assays were collected from
animals administered pure isomers of DNT for 14-days in a repeated
dose oral toxicity study.
2. Materials and methods
These studies were conducted at the US Army Public Health Command in com-
pliance with Good Laboratory Practice standards as described in Title 40, Code of
Federal Regulations (CFR), Part 792.
2.1. Materials
2.1.1. Test substances
Neat 2,4-DNT (CAS # 121-14-2; lot#03718EH; purity 99.0%), 2,3-DNT (CAS #
602-01-7; lot#04918JQ; purity 99.9%), 3,4-DNT (CAS # 610-39-9; lot#05713CA;
purity 99.9%), and 2,6-DNT (CAS # 606-20-2; lot#08328CR; purity 99.8%) were pur-
chased from Sigma–Aldrich, 3050 Spruce Street, St. Louis, MO 63103. 2,5-DNT (CAS #
619-15-8; lot#15317-24; purity 99.3%) and 3,5-DNT (CAS # 618-85-9; lot#15317-8;
purity 99.8%) were produced by SRI International, 333 Ravenswood Avenue, Menlo
Park, CA 94025.
2.1.2. Assay materials
The positive control for the genotoxicity assays, ethylmethane sulfonate
(EMS) (CAS# 62-50-0, lot 1338043) was purchased from Sigma–Aldrich
(St.  Louis, MO). MicroFlow Plus Kits® (lots: anticoagulant 080811/080305,
buffer 21022102/2102204, RNase 070906/080530, rat antibody 99554,
platelet antibody 03952, DNA stain 080408/080919, positive control
RP0408, negative control RN0408) were purchased from Litron Laboratories
(Rochester, NY). CometAssay® kits (lots: lysis buffer 13782J7/17176L8, slides
14252M7/14816B8/16650J8/19771M9, LMagarose 14590A8/19423K9, SYBR
Green 14537A8/16651J8, control cells 13633J7) were purchased from Trevigen,
Inc. (Gaithersburg, MD). Additional chemicals: phosphate buffered saline (lot
ATG32393), ethylenediaminetetraacetic acid (EDTA) (CAS# 60-00-4, lot 1359870),
sodium hydroxide (CAS# 1310-73-2, lot 077K-18221), dimethyl sulfoxide (DMSO)
(CAS# 67-68-5, lot 083108), methanol (CAS# 67-56-1, lot BO516227), and ethanol
(CAS# 64-17-5, lot 020K3658) were purchased from Sigma–Aldrich (St. Louis, MO).
2.1.3. Test animals
These in vivo genotoxicity assays were conducted as part of a study on the
repeated dose toxicity of DNT isomers, the results of which are reported in detail
elsewhere [20]. The study was conducted in two phases, testing three isomers in
each phase. One hundred and twenty-six male Sprague-Dawley rats (43–45 days
old 151–175 g) were obtained from Charles River Laboratories, Wilmington, MA for
each phase. Male rats were selected for use due to their potential for greater sensitiv-
ity in these assays. The cancer bioassays indicated gender difference in the incidence
of  liver tumors [4]. Gender differences in metabolism and enterohepatic cycling also
indicate that the amount of active metabolite produced by males is greater than that
of females [18]. The Attending Veterinarian examined the animals and found them
to  be in acceptable health. The animals were acclimatized for 7 days upon arrival. For
each phase, animals were randomly distributed using the LABCAT® randomization
program into six treatment groups per isomer and three control groups (corn oil
control, negative control, and positive control) consisting of six rats each. Rats were
distributed into groups according to body mass the day before the start of dosing.
To  facilitate scheduling of necropsies, the animals were then divided into six exper-
imental start dates, with one animal from each treatment group per start date. The
rats  were seven weeks old and weighed 262 ± 29.7 and 260 ± 17.9 g at the start of the
study for phase I and II, respectively; body mass did not differ between treatment
groups at the start of the study. Housing conditions were maintained at 64–79 ◦F,
30% to 70% relative humidity with a 12-h light/dark cycle. A certified pesticide-free
rodent chow (Harlan Teklad® , 8728 C Certified Rodent Diet) and drinking quality
water were available ad libitum. Rats were housed individually in suspended poly-
carbonate boxes with Harlan Sani-Chip® bedding. All animal investigations were
conducted in an American Association for the Accreditation of Laboratory Animal
Care  (AALAC) accredited facility with approval of the Institutional Animal Care and
Use Committee. Investigations were conducted in compliance with DOD and federal
statutes and regulations pertaining to experiments involving animals and adhered
to principles stated in the Guide for the Care and Use of Laboratory Animals [21].
2.2.  Methods
2.2.1. Test article administration
Three solutions/suspensions in corn oil were prepared for each isomer and ana-
lyzed to verify concentration, homogeneity, and stability. The test articles were
administered once daily for 14 days using a syringe attached to a 16 gauge gav-
age  needle. Animals were euthanized the morning following administration of the
final dose. A final dose was not administered 1–3 h prior to necropsy because this
dose was  deemed to be of little value given the complex metabolism of DNTs which
requires more time to produce the active metabolite. Unlike other compounds which
typically induce UDS after 1–2 h, DNT induced UDS is delayed for 12 h [22,23], indi-
cating that delayed sampling is appropriate for this compound. Dosing volume was
calculated based on the most recent body mass measurement. The corn oil control
group was given an equivalent volume as the highest dose group for each phase (6.9
and 9 ml/kg, respectively). Dose levels were selected based on reported LD50 values
and  an acute range finding study; and were set at a maximum of 1/2 or 1/4 of the
LD50. The test groups were as shown in Table 1.
A  60 mg/ml  solution of ethylmethane sulfonate (EMS) in filtered water was  pre-
pared fresh each day for use as the positive control solution. This solution was used
within one hour of preparation. EMS  was administered at a dose of 200 mg/kg based
on  daily rat mass and volume of solution. Each positive control animal was  orally
dosed approximately 24 and 4 h prior to being euthanized.
2.2.2. Peripheral blood micronucleus assay
The micronucleus assay was conducted on peripheral blood from the top three
surviving dose groups for each isomer (see Table 1) and the control groups using
the  MicroFlow Plus Kit® (Litron Laboratories, Rochester, NY) following the manu-
facturer’s instructions [24]. Briefly, approximately 120 l of peripheral blood was
collected on the day of necropsy from the saphenous vein by puncturing the vein
with an 18 gauge needle. The blood was collected using a pipette with a tip pre-
coated in anti-coagulant. The blood was placed in a microcentrifuge tube containing
0.35 ml  of anticoagulant and stored at 4–6 ◦C prior to fixing. The blood/anticoagulant
was  fixed by rapidly pipetting 180 l of blood/anticoagulant into centrifuge tubes
containing 2 ml  of methanol at −80 ◦C, vortexing briefly, and returning to −75 to
−85 ◦C for storage until analysis. On the day of analysis by flow cytometry, the blood
samples were washed out of fixative, treated with RNase A, surface marker anti-
bodies conjugated with fluorescein isothiocyanate (FITC) and phycoerythrin (PE),
and  a DNA staining solution (propidium iodide, PI) to dye micronuclei. Anti-CD71-
FITC antibodies were used to distinguish mature erythrocytes (CD71-negative) from
reticulocytes (CD71-positive), while PI was used to detect cells with DNA. Anti-
platelet-PE was used to detect and remove platelets from the analysis. Therefore,
the  population of interest, micronucleated recticulocytes (MN-RET), was identified
as  those cells having high levels of both CD71-FITC and PI-associated fluorescence.
Prior to analysis of samples, the flow cytometer (Coulter Epics XL/MCL; Beckman
Coulter, Miami, FL) was set-up and calibrated using the kit provided standards. Anti-
CD71, anti-platelet-PE and PI fluorescence signals were detected in the FL1, FL2 and
FL3 channels, respectively. A total of 20,000 MN-RETs were analyzed per sample.
The  data collected from the micronucleus assay were expressed as the percentage
of reticulocytes with micronuclei (%MN-RET). The percent of recticulocytes (%RET)
was  also calculated as an indicator of effects on hematopoiesis.
2.2.3. Comet assay
The Comet assay was  used to assess DNA damage in liver cells from rats in
the  top three surviving treatment groups for each isomer (see Table 1) and control
rats  using the CometAssay® kit from Trevigen (Gaithersburg, MD). To create a sin-
gle  cell suspension of liver cells, a small portion (1–2 g) of the left lateral lobe of
the  liver was  removed, rinsed with ice-cold mincing buffer (1X PBS, 20 mM EDTA)
and finely minced. The minced tissue was then pressed through a 70 m cell sieve
and  the suspension washed twice to remove residual blood and cellular debris by
centrifuging at 55 × g for 5 min at 4 ◦C. The pellet was re-suspended in 1X PBS for
use in the assay. The assay was performed according to the manufacturer’s instruc-
tions. Briefly, following isolation the cell suspension was mixed with low melting
temperature agarose at a ratio of 1:10 (v/v) and pipetted onto the commercially pre-
pared slides. Slides were placed flat at 4 ◦C in the dark for 30 min. Slides were then
placed in pre-chilled Lysis Solution at 4 ◦C for 60 min. Slides were then immersed
in  freshly prepared Alkaline Unwinding Solution for 60 min at room temperature in
the  dark. Slides were then transferred to a horizontal electrophoresis apparatus and
electrophoresed for 60 min  at 0.7 V/cm, 296–300 mAmps at 4–8 ◦C. After removal
from the electrophoresis tank, the slides were rinsed in distilled water, immersed in
70%  ethanol for 5 min  and dried on a slide warmer at 37 ◦C. Slides were stained with
SYBR green and visualized using an epifluorescence microscope (Olympus BH-2). To
quantify the amount of DNA damage, 75 cells from each slide (2 slides per animal)
were read using DNA damage analysis software (CometScore, TriTek Corp., Sumer-
duk, VA). To quantify DNA damage percent tail DNA (TDNA) and Olive tail moment
(OTM) were measured.
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Table 1
Summary of study design.
Isomer Study phase Dose group (mg/kg-day) Dose concentration (mg/ml) Dosing volume (ml/kg) Survival Dose group selected for use in assays
2,3-DNT I 17 5 3.4 6/6
34 5 6.9 6/6
69 20  3.4 6/6 *
138 20 6.9 6/6 *
275 80 3.4 6/6 *
550 80 6.9 0/6 NA
3,4-DNT I 7 2 3.4 6/6
14 2 6.9 6/6
28 8 3.4 6/6
57 8  6.9 6/6 *
113 32 3.4 6/6 *
227 32 6.9 6/6 *
2,6-DNT I 4 2 3.4 6/6
7  2 6.9 6/6
14 7  3.4 6/6
35  7 6.9 6/6 *
68  32 3.4 6/6 *
134 32 6.9 6/6 *
2,4-DNT II 9 2 4.5 6/6
18  2 9.0 6/6
36  8 4.5 6/6 *
71  8 9.0 6/6 *
142 32 4.5 6/6 *
284 32 9.0 0/6 NA
2,5-DNT II 10 2.5 4.5 6/6
19  2.5 9.0 6/6
39  10 4.5 6/6
77  10 9.0 6/6 *
154 40 4.5 6/6 *
308 40 9.0 5/6 *
3,5-DNT II 5 2 4.5 6/6
10  2 9.0 6/6 *
19  8 4.5 6/6 *
39  8 9.0 5/6 *
77  32 4.5 0/6 NA
155 32 9.0 0/6 NA
2.2.4. Liver histopathology
Tissues were collected and appropriately preserved in 10% buffered formalin,
packaged and shipped to Comparative Biosciences, Inc (Sunnyvale, CA) for process-
ing. Cassettes containing tissues were processed through a graded series of alcohols
using an automated processor, then oriented and embedded in paraffin, sectioned
at  approximately 3–5 m thickness, stained with hematoxylin and eosin and cover-
slipped. Evaluation of liver tissue for all dose groups and controls used in the Comet
assay was  performed by an American College of Veterinary Pathology board certified
military veterinary pathologist. The severities of lesions per tissue were recorded
as:  Grade 0 = normal, Grade 1 = minimal/trace, Grade 2 = mild, Grade 3 = moderate,
Grade 4 = severe.
2.2.5. Statistical analyses
Results are presented as animal means ± standard error of the mean (SEM) for
each treatment group. For parameters with multiple samples or measurements per
animal, sample means were calculated prior to analysis and all analyses were con-
ducted on the animal means of the sample means such that the animal was treated
as the experimental unit for all analyses. Statistical analyses were performed using
SPSS® 16.0 software. One-way analysis of variance (ANOVA) was  used to test for dif-
ferences among treated and control groups within each phase. If the ANOVA showed
significant differences, post hoc analysis was conducted using a Tukey’s multiple
comparison tests. Statistical significance was defined as P < 0.05.
3. Results
3.1. Mortality and clinical observations
Mortality occurred in all animals administered 2,3-DNT at
550 mg/kg-day after 2–4 days of dosing. Clinical signs of toxicity,
including cyanosis, lethargy, squinting, rapid respiration/labored
breathing, hunched posture, dark urine, and chromodacryorrhea,
and were observed in the 550 mg/kg-day dose group. Due to the
mortality in the 550 mg/kg-day group, the 275 mg/kg-day dose was
the highest dose used in the genotoxicity assays as it was the max-
imum tolerated dose (MTD) for 14-days.
Clinical signs of toxicity, including cyanosis, lethargy, dark urine,
facial twitching, and hypoactivity/staring were observed in rats
administered 3,4-DNT at 227 mg/kg-day. Dark urine was observed
in the 113 mg/kg-day group.
No overt clinical signs of toxicity were observed in any 2,6-DNT
dose groups. Dark urine and dried red material around nose were
observed in animals in the 134 mg/kg-day group.
Mortality occurred in all animals dosed with 2,4-DNT at
284 mg/kg-day after 2–7 days of dosing. Clinical signs of toxic-
ity, including cyanosis, squinting, lethargy, prostrate posture, rapid
respiration/labored breathing, hunched posture, dark urine, red
discharge around nose/dried red material around nose, and orange
feces, limb paralysis were observed in the 284 mg/kg-day dose
group. Observations in lower dose groups were limited to dried
red material around nose and barbering.
Clinical signs of toxicity, including cyanosis, squinting, prostrate
posture, rapid respiration/labored breathing, hunched posture,
dark urine, red discharge around nose/dried red material around
nose, orange feces, and soft feces or diarrhea were observed in
the 154 and 308 mg/kg-day 2,5-DNT dose groups. Observations in
lower dose groups were primarily limited to dried red material
around nose, and barbering.
Mortality occurred in all animals dosed with 3,5-DNT at 77
and 155 mg/kg-day after approximately 8 and 4 days of dosing,
respectively. Clinical signs of toxicity, including cyanosis, squinting,
prostrate posture, rapid respiration/labored breathing, hunched
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posture, dark urine, red discharge around nose/dried red mate-
rial around nose, and orange feces were observed in the 77 and/or
155 mg/kg-day dose groups. In addition, animals in the 39, 77, and
155 mg/kg-day dose groups exhibited signs of neurological impair-
ment that progressed rapidly from facial twitching, head bobbing,
tilted head carriage, and uncoordinated movement, to loss of motor
control, and paralysis of the thoracic limbs. Observations in lower
dose groups were primarily limited to dried red material around
nose, and barbering.
Due to mortality in the highest dose groups of 2,3-, 2,4-, and
3,5-DNT, lower dose groups were selected for use in the genotox-
icity assays for these isomers (see Table 1). With the exception of
2,6-DNT, the pattern of mortalities and clinical signs indicate that
the highest dose groups selected for use in the genotoxicity assays
represent a 14-day maximum tolerated dose (MTD).
3.2. Peripheral blood micronucleus assay
For 2,5-DNT, distortion was observed in the flow cytometry
data plots such that the NCE population pulled upward into the
RET population, artificially increasing the frequency of MN-RET
reported. Because the distortion increased in a dose-dependent
manner, the effect was believed to be treatment related. Simi-
lar patterns of distortion have been observed with compounds
that induce methemoglobinemia, suggesting that the pattern is
autofluorescence associated with methemoglobinemia. As 2,5-
DNT induced severe cyanosis and anemia and DNTs have been
reported to induce methemoglobinemia [3],  the distortion in plots
for 2,5-DNT was likely due to autofluorescence associated with
methemoglobinemia. Because the autofluorescence caused a dose-
dependent artificial increase in the frequency of MN-RET reported,
post-acquisition adjustments were made to the gating parame-
ters to accommodate for a modest degree of autofluorescence.
To prevent NCEs with autofluorescence being incorrectly scored
as RETs, the RET population was restricted to high CD71 positive
RETs. Due to the high likelihood that all of the DNT isomers induce
methemoglobinemia and observations of cyanosis, gating param-
eters adjusted to accommodate autofluorescence were used in
the analysis for all data. The 308 mg/kg-day group was dropped
from analysis as the autofluorescence could not be corrected.
Despite apparent correction of autofluorescence in the 154 mg/kg-
day 2,5-DNT group, there was  a two  fold increase (P = 0.025) in the
frequency of MN-RET (Table 2). Treatment with 2,3-DNT, 3,4-DNT,
2,6-DNT, 2,4-DNT and 3,5-DNT did not increase the frequency of
MN-RET relative to the concurrent corn oil control (Table 2). There
were approximately 1.5 and 1.8 fold increases in MN-RET frequency
in the highest doses of 2,4-DNT and 3,5-DNT, respectively; how-
ever, these increases were not statistically significant. Although a
sample size of six would suggest sufficient power to detect approx-
imately 2 fold differences in the flow cytometric assay, power was
limited by inter-animal variability which ranged from 0.03 to 0.12
[25].
The percentage of reticulocytes (%RET) was increased relative to
the corn oil control group at the highest dose for 2,6-DNT (P = 0.002)
and 2,4-DNT (P < 0.001) and was increased at all doses for 2,5-DNT
(P < 0.001) (Table 2). Reticulocyte frequency did not change relative
to the concurrent control group for 2,3-DNT, 3,4-DNT or 3,5-DNT.
3.3. Comet assay
For 2,6-DNT, TDNA and OTM were increased (P < 0.001 and
P < 0.001, respectively) in all dose groups relative to the corn oil
control group and both measures demonstrated a dose response
such that DNA damage increased with increasing dose (Fig. 1). 2,6-
DNT doses of 35, 68, and 134 mg/kg-day resulted in 2.89, 3.38, and
3.64 fold increases in TDNA values, respectively, relative to the
concurrent corn oil control (Fig. 1, Table 3). TDNA did not differ
significantly between treated groups and concurrent controls for
the minor isomers, with fold increases ranging from 0.92 to 1.96
(Table 3). A 2.08 fold increase in TDNA was  observed for 2,4-DNT,
however, this difference was not statistically significant, possibly
due to large animal to animal variability.
Table 2
Results of the rat peripheral blood micronucleus assay.
Study phase Compound Dose (mg/kg-day) n MN-RET (%) RET (%)
Mean SEM Mean SEM
I Corn oil control 6 0.12 0.024 0.82 0.02
2,3-DNT 69 6 0.12 0.033 0.78 0.17
138 6 0.11 0.019 0.89 0.18
275 6 0.12 0.019 0.98 0.21
2,6-DNT 35 5 0.15 0.032 1.03 0.17
68  5 0.15 0.041 0.92 0.41
134 5 0.13 0.012 3.02* 0.74
3,4-DNT 57 6 0.12 0.026 0.80 0.23
113 6 0.09 0.003 1.11 0.23
227 6 0.13 0.018 1.21 0.13
II Corn oil control 6 0.12 0.019 0.96 0.16
2,4-DNT 36 6 0.11 0.016 0.85 0.12
71  6 0.12 0.016 1.09 0.20
142 6 0.18 0.018 3.30* 0.45
2,5-DNT 77 6 0.18 0.028 4.97 0.62
154 6 0.24* 0.039* 6.89* 0.75
308 5 9.02* 1.52
3,5-DNT 10 6 0.10 0.016 1.17 0.23
19  6 0.10 0.012 1.88 0.33
39 6 0.21 0.050 0.82 0.36
MN-RET (%): percent micronucleated reticulocytes, RET (%): percent reticulocytes.
* P < 0.05.
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Fig. 1. DNA damage in the liver measured using the Comet assay after 14-days of oral administration of isomers of DNT to male Sprague-Dawley rats. Data are presented
as  means ± SEM for each dose group. Means and statistics were conducted noting the hierarchical nature of the data, taking means by slide, animal, group. The study was
conducted in two phases (I and II); statistical analyses were conducted within phases between treated groups and their respective control group. CO1: corn oil control 1;
CO2:  corn oil control 2; EMS  1: ethylmethane sulfonate 1 (positive control); EMS  2: ethylmethane sulfonate 2 (positive control). *P < 0.05.
Table 3
Results of the in vivo liver Comet assay.
Study phase Compound Dose (mg/kg-day) n TDNA Fold increase OTM
Mean SEM Mean SEM
I Corn Oil Control 6 12.73 1.32 6.81 0.80
EMS  Control 200 6 84.99 5.65 6.68 96.48* 14.99
2,3-DNT 69 6 16.20 1.58 1.27 8.39 0.63
138 6 24.96 6.42 1.96 21.32 10.55
275  6 17.88 2.70 1.40 11.35 2.74
2,6-DNT 35 6 36.75 4.59 2.89 32.08 5.15
68  6 43.00 2.53 3.38 38.86 6.03
134 6 46.32 1.79 3.64 44.32 4.40
3,4-DNT 57 6 16.28 1.88 1.28 9.29 1.33
113 6 19.33 2.03 1.52 12.59 1.66
227 6 21.96 4.63 1.73 17.00 6.29
II  Corn Oil Control 6 3.01 0.46 2.16 0.35
EMS  Control 200 6 72.27* 4.54 24.01 68.22* 4.63
2,4-DNT 36 6 4.35 0.38 1.45 3.21 0.30
71  6 5.44 0.91 1.81 4.34 0.81
142 6 6.25 1.34 2.08 5.03 1.25
2,5-DNT 77 6 3.40 0.91 1.13 2.63 0.75
154 5 3.64 0.43 1.21 2.74 0.35
308 6 3.97 0.95 1.32 3.23 0.75
3,5-DNT 10 6 3.09 0.63 1.03 2.32 0.51
19  6 3.47 0.44 1.15 2.54 0.38
39  6 2.76 0.41 0.92 1.85 0.25
TDNA: % Tail DNA; OTM: Olive Tail Moment; EMS: ethylmethane sulfonate
* P < 0.05
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3.4. Liver cytotoxicity
2,6-DNT showed moderate single cell necrosis in 5/6 rats in each
of the 68 and 134 mg/kg-day dose groups. For 2,4-DNT, trace to
mild single cell necrosis was noted in 3/6 at 36 mg/kg-day, 1/6
at 71 mg/kg-day, and 4/6 at 142 mg/kg-day. Trace apoptosis was
noted in 1/6 rats in each of the 36 and 71 mg/kg-day of 2,4-DNT
dose groups. No treatment related liver toxicity was  noted in the
2,3-DNT, 3,4-DNT, 2,5-DNT, or 3,5-DNT dose groups used in the
micronucleus or Comet assays.
4. Discussion
This study, the first in vivo genotoxicity assessment for the
minor isomers, demonstrated that treatment with the minor iso-
mers (2,3-DNT, 3,4-DNT, 2,5-DNT, 3,5-DNT) did not induce DNA
damage in liver cells or increase the frequency of MN-RET in the
peripheral blood of treated rats. These results indicate that the
minor isomers are not genotoxic at the doses tested. The major
isomers, 2,4- and 2,6-DNT, have been the subject of more testing
than the minor isomers. As in the in the present study, the major
isomers have previously given negative results in the bone mar-
row or peripheral blood micronucleus assays [26–29].  The negative
results in the peripheral blood micronucleus assay suggest that the
active metabolites of DNT, produced through enterohepatic circu-
lation [18,19],  did not reach the bone marrow. Active metabolites
produced in the liver are often short lived and the concentration
reaching the bone marrow does not allow for sufficient exposure
to induce MN [28,30]. Active metabolites produced in the liver may
also be bound to liver tissue [18], never entering systemic circula-
tion. It may  also be that the bone marrow is not a target organ
for DNTs. The hematological effects of several isomers, including
increased %RET; however, indicate that the bone marrow is a tar-
get organ. The effects on the hematopoietic system may, however,
be due to the parent compound.
Many of the effects of dinitrotoluenes on the hematopoietic
system are associated with the induction of methemoglobinemia
[3].  Although it did not pose a problem in tests conducted with
2,4,6-trinitrotoluene (TNT) which gave clearly negative results,
methemoglobinemia has been cited as a contributor to false
positive results in micronucleus assays [31–33].  Two types of
methemoglobinemia-associated false positive results occur in flow
cytometry assays: an artificial increase in MN-RET counts mea-
sured by flow cytometry due to autofluorescence; and an actual,
though non-genotoxic, increase in MN-RET that is due to distur-
bance of erythropoiesis. In the former, fluorescence associated
with porphyrins and bilirubin resulting from methemoglobine-
mia  related hemolysis may  disrupt micronucleus assays. This type
of methemoglobinemia associated fluorescence was  observed in
the present study; however, post-acquisition adjustments were
made to gating parameters to reduce or eliminate the contribu-
tion of this fluorescence to detection of micronuclei. In the latter,
the increases in MN-RET are due to reticulocytosis resulting from
methemoglobinemia associated hemolysis. The increase in pro-
duction of RETs possibly resulting from tissue hypoxia induced
stimulation of erythropoietin secretion [33]. Accelerated prolif-
eration and differentiation of erythrocytes can lead to increased
MN-RETs due to more opportunities for spontaneous errors in cell
division and errors during enucleation [32,33].  Stimulation of ery-
thropoiesis by erythropoietin may  also reduce the efficiency of
DNA repair and, through the suppression of apoptosis, possibly
enable the survival of damaged cells [34,35]. Treatment with ery-
thropoietin and stimulation of erythropoiesis has been shown in
mice to increase micronuclei frequency, theoretically as a result
of reduced efficiency of DNA repair [32]. In the case of aniline,
however, the compound did not exhibit in vivo clastogenic activ-
ity in the mouse bone marrow, suggesting a non-genotoxic origin
for the observed micronuclei [32]. In the present study, several
isomers (2,6-DNT, 2,4-DNT, 2,5-DNT) demonstrate increases in
reticulocytes, while only 2,5-DNT has apparent, though likely false,
increases in micronuclei. As with aniline, the response observed in
the micronucleus assay is likely due to disruption of erythropoiesis
rather than genotoxicity.
DNA damage was detected in liver cells using the Comet assay
following in vivo administration of 2,6-DNT, but not 2,4-DNT.
The results are in agreement with recent work which showed an
increase in the incidence on micronucleated hepatocytes follow-
ing a single dose of 2,6-DNT as low as 50 mg/kg or repeated doses
as low as 33 mg/kg-day [27–29].  In contrast to the current study,
previous reports indicated that 2,4-DNT is genotoxic in the rat liver
micronucleus assay at 200 mg/kg [28]. The discrepant results for
2,4-DNT may  be due to differences in doses used (142 mg/kg-day
vs. 200 mg/kg), strain differences [30], or differences in the types
of damage detected [36]. The negative result for 2,4-DNT is sup-
ported by in vivo hepatocyte initiation-promotion assays in which
2,4-DNT demonstrated no initiating activity and the only carcino-
genesis study conducted with pure 2,4-DNT in which 2,4-DNT did
not induce hepatocarcinomas [6–9].
The necrosis associated with 2,4-DNT and 2,6-DNT may  have
confounded the results as excessive cytotoxicity and necrosis have
been implicated in false positive results in the in vitro Comet assay
[37]. Recent work has, however, suggested that, at least in the liver,
tissue cytotoxicity does not lead to increased DNA migration in the
in vivo Comet assay [29,38].  Additionally, work by Rothfuss et al.
[29] demonstrated an increase in DNA damage in the in vivo liver
Comet assay for rats exposed to 100 mg/kg-day of 2,6-DNT for 3
days or 33 mg/kg-day for 29 days [28,29].  Thus, the positive result
for 2,6-DNT in the current study appears reliable despite cytotox-
icity in two of the doses used. Cytotoxicity and necrosis have also
been reported to cause a decrease in DNA migration if cells are
collected in advanced stages of necrosis, resulting in false nega-
tives [39]. Although necrosis was  noted in all doses for 2,4-DNT,
the finding was trace to mild and there was no increase in serum
liver enzymes in any dose group [20]. In addition, for both 2,4-DNT
and 2,6-DNT, the data exhibited a unimodal response with all cells
showing similar levels of DNA migration rather than a bimodal dis-
tribution expected with necrosis [37]. Therefore, the hepatotoxicity
of 2,4-DNT and 2,6-DNT did not give misleading results in the in vivo
Comet assay.
These data support a body of research indicating that 2,6-
DNT was  responsible for the hepatocarcinogenicity observed in
studies using TG-DNT and mixtures of 2,4-DNT and 2,6-DNT e.g.
[6–9,18,19]. Much of that work focused on the major isomers,
demonstrating that 2,6-DNT, unlike 2,4-DNT, is a complete carcino-
gen and causes hepatocellular carcinomas [6–9]. In the only studies
investigating the role of all the individual isomers, 2,4-DNT and the
minor isomers were shown to have no detectable hepatocyte initi-
ating activity [6].  The negative results for the minor isomers in the
current study indicate that the minor isomers are not genotoxic,
adding to the weight of evidence indicating that the carcinogenicity
of TG-DNT is attributable to the 2,6-DNT isomer.
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